NAD+ IV Therapy in Australia: What's Actually Happening

What This Article Covers

Over the past two to three years, Australia has seen a rapid expansion of "longevity" and wellness clinics offering intravenous NAD+ infusions alongside peptides, red light therapy, and cryotherapy — a boom significant enough that it triggered a national broadcaster investigation, two Therapeutic Goods Administration (TGA) safety alerts, and open regulatory scrutiny of how doctors are prescribing unapproved products through telehealth. This piece looks at what's actually documented: the size and shape of the industry, what Australian regulators have and haven't approved, what the clinical evidence for IV NAD+ currently shows, and the real safety incidents that have emerged from the broader injectable-wellness market it sits inside.

A Fast-Growing, Thinly Regulated Market

An ABC Four Corners investigation broadcast in 2026 identified roughly 100 wellness and longevity operators now offering anti-aging IV drips, peptide prescriptions, and related services across Australia — a category that barely existed in its current form a few years earlier. NAD+ infusions are typically marketed as boosting cellular energy, supporting "healthy aging," and aiding recovery, and clinics charge upwards of AUD $500 per treatment, often sold in multi-session packages. The reporting found a pattern repeated across clinics: confident marketing language about cellular repair and anti-aging, paired with little disclosure of how thin the human evidence base actually is.

The Regulatory Picture

Australia's regulatory split matters here. The TGA regulates therapeutic goods (the products and how they're advertised); the Australian Health Practitioner Regulation Agency (AHPRA) regulates the conduct of registered doctors who prescribe or administer them. That gap is central to how NAD+ IV therapy currently operates in Australia. The TGA has issued a safety alert stating that NAD, NAD+, NADH, and NMN are not approved ingredients for listed medicines in Australia — meaning products making these claims generally lack Australian Register of Therapeutic Goods (ARTG) registration and have not been formally assessed for safety, quality, or efficacy in that category. The agency's separate guidance on advertising IV drip therapies classifies them as therapeutic goods subject to the Therapeutic Goods Advertising Code, with fines and potential prosecution for non-compliant marketing claims. There has been one notable regulatory shift: in December 2025, NMN was approved as a permissible ingredient for listed (oral) medicines, reversing the earlier blanket restriction — with one Australian supplier authorized to sell an oral NMN product. That change applies to oral, listed-medicine NMN, not to IV NAD+ infusions, which remain outside standard TGA approval and reach patients instead through doctors prescribing or administering them as unapproved products — a pathway the TGA's own chief medical adviser has noted falls into a regulatory gap, since the agency does not regulate the clinicians themselves.

What the Evidence Actually Shows

The clinical case for IV NAD+ in healthy adults remains unresolved. ABC's reporting cited a recent assessment in the journal Ageing Research Reviews concluding that whether boosting NAD+ levels produces genuine anti-aging or wellness benefits is "inconclusive." International longevity researcher Professor Luigi Fontana was blunter, stating there is no human clinical trial evidence that NAD+ delivers health or anti-aging benefits, and that he was not aware of safety data specific to infusions. Preclinical and animal studies have shown biologically plausible effects on cellular energy metabolism, but controlled, adequately powered human trials — particularly placebo-controlled studies looking at meaningful long-term outcomes rather than short-term biomarkers — are still largely absent. That evidentiary gap is the throughline across nearly every independent review of the category to date.

The Telehealth Prescribing Loophole

A specific mechanism the investigation documented: a Four Corners reporter obtained prescriptions for multiple unapproved peptides through a Queensland telehealth clinic after a roughly AUD $400 blood test, a written questionnaire, and a phone-only consultation — no video required. The prescribing doctor acknowledged that peptides are "very controversial" in Australia and should generally be a last resort, yet still issued a four-to-six-week "stack" costing AUD $1,181. AHPRA's chief executive, Justin Untersteiner, said some practitioners "may be seeking to exploit the latest health trends by putting profits ahead of patients," and confirmed the agency has open notifications relating to peptide prescribing and supply. While that specific case involved peptides rather than NAD+, it illustrates the broader prescribing pathway — telehealth plus off-label doctor sign-off — through which many unapproved longevity-clinic products, including NAD+ infusions, reach Australian patients outside conventional drug-approval channels.

Risks Beyond the Infusion Bag

IV NAD+ carries standard infusion risks — injection-site reactions and infection — and researchers have flagged, without direct supporting data from NAD+ patients specifically, that NAD+'s role in DNA repair pathways is also exploited by cancer cells, an area authorities say hasn't been specifically studied in people who've received these infusions. The wider unregulated injectable market this industry sits within has produced more concrete harm: Victorian health authorities reported seven hospitalizations for acute liver toxicity linked to counterfeit, black-market retatrutide (a weight-loss peptide, distinct from NAD+), with cases emerging within weeks of use. Nationally, the TGA has destroyed more than 94,500 unapproved peptide products this year and made seizures worth AUD $120,000 in illicit peptides and steroids, underscoring how much of this broader market operates outside any quality control.

Bottom Line

NAD+ IV therapy has become a visible, fast-growing part of Australia's wellness and longevity-clinic sector, but it remains a product without TGA approval, delivered through a prescribing pathway regulators themselves describe as having gaps, and backed by human evidence that independent reviewers and longevity researchers alike call inconclusive at best. Australia's recent move to permit oral NMN as a listed-medicine ingredient shows regulators are willing to approve specific longevity-adjacent compounds when the evidence and category fit — but that approval has not extended to IV NAD+, and documented harms elsewhere in the same unregulated injectable-wellness market (contaminated peptides, hospitalizations, and AHPRA's open prescribing investigations) are a reason for real caution, not just a technicality. Anyone considering IV NAD+ should treat the "cellular anti-aging" framing as unproven marketing, not established science, and should expect no Australian regulatory body to currently vouch for the infusion itself.